S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)

Bibliographic Details
Main Authors: A Silva-Pinto, R Colombatti, A Pasanisi, F Arcioni, L DeBonnett, W Soliman, R Sarkar, R Cançado
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000821452.65842.6a